Imbalance in DNA repair machinery is associated with BRAF V600E mutation and tumor aggressiveness in papillary thyroid carcinoma

• Published in: Molecular and cellular endocrinology Vol. 472; pp. 140 - 148
• Main Authors: Lutz, Bruna S, Leguisamo, Natalia M, Cabral, Nicole K, Gloria, Helena C, Reiter, Keli C, Agnes, Grasiela, Zanella, Virgilio, Meyer, Erika L S, Saffi, Jenifer
• Format: Journal Article
• Language: English
• Published: Ireland 05.09.2018
• Subjects: Prognosis; Papillary thyroid cancer; DNA repair; BRAF(V600E)
• ISSN: 0303-7207; 1872-8057
• DOI: 10.1016/j.mce.2017.12.004

The involvement of alterations in MLH1, an essential mismatch repair component, in BRAF mutated papillary thyroid carcinoma (PTC) has been suggested to be associated with features of tumor aggressiveness. Thirty-two PTC and surrounding normal thyroid tissues were evaluated for 11 representative DNA repair genes expression. BRAF mutational status assessment and clinicopathological correlations were evaluated for their gene and protein expression. BRAF PTC is associated with lower levels of XPD and MLH1 gene expression. Decrease in MLH1 and XPD mRNA levels in BRAF PTC (but not their protein products) are associated with predictors of poor patient outcomes. Considering the complete subset of patients, MGMT and XRCC2 genes were shown down and upregulated, respectively, in PTC tissues. Low expression of MGMT gene and weak XRCC2 protein expression were correlated with characteristics of tumor aggressiveness. These results suggest that an imbalance in DNA repair gene expression in PTC is associated with aggressive clinicopathological features and BRAF mutation.